Dr Peter Jackson (Chairman) was previously Chief Executive Officer of Reaxa and was formerly Vice President of Avecia's Pharmaceutical Products business unit. One of Redx Pharma's founders and co-inventor of the Redox Switch™ technology, Dr Jackson provides business and commercial consultancy to the company. His other lifescience directorships include Blackley Holdings Ltd, ADC Biotechnology Ltd and Yorkshire Process Technology Ltd. Dr Jackson is also a former director of the National Skills Academy for Process Industries.
Dr Neil Murray (CEO) is a founding partner of Essential Science Ltd, a consulting practice providing expert, hands-on support in corporate and business development, partnering and technology exploitation in the Life Sciences, Biotechnology and Drug Discovery and Development sectors. He is also the founder of PharmEcosse Ltd, developers of a novel scar reduction and prevention therapeutic. His areas of expertise include the application of platform technologies in drug research & development, overall drug development strategy, planning & management, portfolio development and corporate and business development across multiple therapies and markets. Dr Murray has more than 20 years experience in the pharmaceutical industry holding senior positions with Solutia Inc, Vernalis Ltd (formerly Vanguard Medica Ltd), Sigma-Aldrich Fine Chemicals and Glaxo-Wellcome Research & Development.
Dr Derek Lindsay (COO) was previously Director of Innovation of Britest Ltd, based in Runcorn, and was formerly R&D Director of Avecia Pharmaceutical Products. Dr Lindsay is one of the founders of Redx Pharma. In addition to his role as COO of Redx Pharma, Dr Lindsay is Managing Director of Redx Oncology Ltd.
Dr Peter Jackson (Chairman), as above
Dr Neil Murray (CEO), as above
Dr Derek Lindsay (COO), as above
Norman Molyneux (CFO) qualified as an accountant in 1981 and, since that time, has worked as a management consultant for PricewaterhouseCoopers and has held various board level positions in manufacturing companies. For the last five years, Norman has been Chief Executive of Acceleris Ltd, a corporate finance firm specialising in raising funds for early and development stage businesses.
Dr Philip Gould (Non-Executive Director) is Chief Executive of Jadara Pharma Ltd, based in the north west of the UK and has held a range of scientific and executive roles with pharmaceutical companies Pfizer, Wyeth, Glaxo and Provalis. Dr Gould provides drug development expertise to the company.
Peter McPartland (Non-Executive Director) is an independent venture capital consultant. Originally a graduate pharmacologist, he worked as an investment analyst before receiving his VC training at Schroder Ventures (which later became Permira). He went on to become a co-founder and general partner of SV Life Sciences (one of the world's largest specialist VC firms with over $2billion under management). Peter has established a strong track record in early stage drug discovery and development, and has been a director of a number of leading companies in the field, including Shire Pharmaceuticals and Chiroscience. Currently, Peter is a non-executive director of two other private, UK-based life science companies.
Dennis Hallahane (Non-Executive Director) is an active investor in early-stage companies worldwide. Dennis began his career with Ford Motor Company and then Plessey before embarking on a career in investment management. He successfully ran VC funds backed by the Bank of England and Standard Chartered Merchant Bank investing globally across a diverse range of sectors. In 1998, Dennis co-founded World Class Learning which was successfully sold in 2008 after 10 years of dynamic growth. Dennis maintains a portfolio of investments in early-stage companies and holds a number of non-executive directorships including Redx Pharma.